Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
复制标题
血浆可溶性Fas配体浓度：老年男性降低，胃癌患者升高。
DOI：
10.3892/or.8.2.311
复制
发表时间：
2001
期刊：
影响因子：
4.2
通讯作者：
H. Mochizuki
中科院分区：
文献类型：
--
作者：
T. Ichikura;T. Majima;T. Uchida;E. Okura;T. Ogawa;H. Mochizuki
Fas配体(Fas Ligand，FasL)是一种诱导Fas表达的细胞凋亡的分子，已被发现在包括癌细胞在内的多种细胞中都有表达。膜结合的FasL被切割后释放出可溶性的FasL(SFasL)。尽管在各种疾病中血清或血浆sFasL浓度升高已有报道，但在健康正常人中sFasL浓度仍未得到充分研究。关于肿瘤患者sFasL浓度的报道很少。用双抗体夹心法测定了155例健康志愿者(男70例，女85例，平均年龄41.5±15.4岁)和112例胃癌患者(男76例，女36例，平均年龄62.3±11.5岁)的血浆sFasL浓度。健康志愿者年龄与血浆sFasL浓度呈显著负相关。男性sFasL浓度显著低于女性。分析50岁或以上的男性受试者时，胃癌患者的血浆sFasL水平显著高于健康志愿者，尽管在35岁至49岁的年龄段之间没有显著差异。50岁以上的男性1B期或2期肿瘤患者血浆sFasL浓度显著高于1 A期或3期或4期肿瘤患者。总而言之，在研究血浆sFasL浓度时，应使用年龄和性别匹配的对照。健康志愿者和胃癌患者血浆sFasL的来源及其生理或临床意义尚不清楚。
Fas ligand (FasL), which induces apoptosis against Fas-expressing cells, has been found to be expressed on various cell types including cancer cells. Membrane-bound FasL is cleaved to release soluble FasL (sFasL). Although serum or plasma sFasL concentration has been reported to increase in various diseases, sFasL concentration in healthy normal persons has not been fully studied. There have been few reports on sFasL concentrations in patients with carcinomas. We measured plasma sFasL concentrations using an enzyme-linked immunosorbent assay in 155 healthy volunteers (70 males and 85 females with an average age of 41.5+/-15.4) and 112 patients with gastric carcinoma (76 males and 36 females with an average age of 62.3+/-11.5). A significant negative correlation existed between age and plasma sFasL concentration in healthy volunteers. sFasL concentrations in males were significantly lower than those in females. Plasma sFasL levels were significantly higher in patients with gastric carcinoma than in healthy volunteers when male subjects aged 50 or older were analyzed, although no significant difference existed between the groups in the age bracket of 35 to 49. Male patients aged 50 or older with stage 1B or 2 tumors showed significantly higher plasma sFasL concentrations than those with stage 1A tumors or those with stage 3 or 4 tumors. In conclusion, age- and gender-matched controls should be used when plasma sFasL concentration is investigated. The origin and physiological or clinical significance of plasma sFasL in healthy volunteers and gastric cancer patients remain to be clarified.